Casodex® (Bicalutamide): Overview of a new antiandrogen developed for the treatment of prostate cancer

European Urology

Volumn 31, Issue SUPPL. 2, 1997, Pages 30-39

  Blackledge, G R P ^a   Cockshott, I D ^a   Furr, B J A ^a  

^a ASTRAZENECA   (United Kingdom)

Author keywords

Bicalutamide; Casodex ; Clinical studies; Non steroidal antiandrogen; Preclinical studies; Prostate cancer

Indexed keywords

ACID PHOSPHATASE PROSTATE ISOENZYME; ANTIANDROGEN; BICALUTAMIDE; FLUTAMIDE; PROSTATE SPECIFIC ANTIGEN; ANILIDE; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS;

CANCER SURVIVAL; CASTRATION; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG HALF LIFE; HUMAN; MALE; META ANALYSIS; METASTASIS; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; PROSTATE TUMOR;

ANDROGEN ANTAGONISTS; ANILIDES; ANTINEOPLASTIC AGENTS, HORMONAL; HUMANS; MALE; PROSTATIC NEOPLASMS;

EID: 0031057105     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1159/000474547     Document Type: Review

References (44)